Beijing-based cancer drug developer BeiGene (Beijing) Co., Ltd., backed by Hillhouse Capital and CITIC Private Equity, has completed an initial public offering in the U.S., raising around US$158 million. The company sold 6.6 million shares at US$24 per share, at the upper end of its indicative price range of US$22 to US$24. Its shares began […]

Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.